Karyopharm

Karyopharm reports interim data from eltanexor Phase I/II study
Karyopharm reports interim data from eltanexor Phase I/II study
Clinical Trials Arena
Karyopharm
clinical trials
KPT-8602
myelodysplastic neoplasms
Flag link:
CTOS 2020 – Karyopharm seeks a solid tumour Seal of approval
CTOS 2020 – Karyopharm seeks a solid tumour Seal of approval
EP Vantage
Karyopharm
solid tumors
Xpovio
CTOS
Flag link:
Karyopharm’s Xpovio Wins Second FDA Approval for DLBCL Treatment
Karyopharm’s Xpovio Wins Second FDA Approval for DLBCL Treatment
BioSpace
Karyopharm
FDA
DLBCL
Xpovio
Flag link:
Karyopharm posts positive data from Phase III trial of multiple myeloma drug
Karyopharm posts positive data from Phase III trial of multiple myeloma drug
MedCity News
Karyopharm
Multiple Myeloma
clinical trials
Xpovio
Flag link:
Upcoming events – Karyopharm's myeloma expansion and Pfizer's biz dev news
Upcoming events – Karyopharm's myeloma expansion and Pfizer's biz dev news
EP Vantage
Karyopharm
Xpovio
Multiple Myeloma
Pfizer
Akcea
Ionis Pharmaceuticals
AKCEA-ANGPTL3-Lrx
Flag link:
Biotech's Most Volatile Binary Events for Q1
Biotech's Most Volatile Binary Events for Q1
Motley Fool
FDA
Esperion Therapeutics
Karyopharm
TG Therapeutics
Heron Therapeutics
Flag link:
Karyopharm drug tested in ‘industry-first’ approach to brain cancer
Karyopharm drug tested in ‘industry-first’ approach to brain cancer
Pharmaforum
Karyopharm
Xpovio
brain cancer
Selinexor
clinical trials
glioblastoma
Flag link:
Karyopharm’s Xpovio nabs myeloma nod despite checkered past. But 5th line?
Karyopharm’s Xpovio nabs myeloma nod despite checkered past. But 5th line?
Fierce Pharma
Karyopharm
FDA
Multiple Myeloma
Xpovio
Selinexor
Flag link:
FDA Action Alert: Karyopharm, Merck and Celgene
FDA Action Alert: Karyopharm, Merck and Celgene
BioSpace
FDA
Karyopharm
Selinexor
Merck
relebactam
Celgene
Otezla
Flag link:
The Week Ahead In Biotech: Pending Clinical Readouts In Focus
The Week Ahead In Biotech: Pending Clinical Readouts In Focus
Yahoo/Benzinga
Retrophin
Karyopharm
Celyad
uniQure
Sangamo Therapeutics
Catalyst Biosciences
Novo Nordisk
Reata Pharmaceuticals
Vertex Pharmaceuticals
Bellicum
Gilead Sciences
Jaguar Health
TRACON Pharmaceuticals
FibroGen
Aslan Pharma
ObsEva
Sorrento Therapeutics
Flag link:
Karyopharm gets bump as FDA extends review of selinexor
Karyopharm gets bump as FDA extends review of selinexor
BioCentury
Karyopharm
FDA
Selinexor
Multiple Myeloma
Flag link:
The Week Ahead In Biotech: ASCO Presentations In The Spotlight
The Week Ahead In Biotech: ASCO Presentations In The Spotlight
Yahoo/Benzinga
ASCO 2018
European Society of Cardiology
TherapeuticsMD
Abiomed
Incyte
Bluebird Bio
Celgene
Syndax
Loxo Oncology
Exelixis
Karyopharm
Endocyte
Celldex Therapeutics
Jounce Therapeutics
Bristol-Myers Squibb
Nektar
Flag link:
Karyopharm bags a $193M Asian deal for selinexor and followup drug, shares jump
Karyopharm bags a $193M Asian deal for selinexor and followup drug, shares jump
Endpoints
Karyopharm
Selinexor
Ono
Flag link:
Karyopharm shakes off clinical hold for lead cancer med
Karyopharm shakes off clinical hold for lead cancer med
BioPharma Dive
Karyopharm
Selinexor
clinical trials
solid tumors
diffuse large B-cell lymphoma
Multiple Myeloma
Flag link:
FDA orders Karyopharm to halt enrollment for all selinexor trials, citing incomplete safety warning
FDA orders Karyopharm to halt enrollment for all selinexor trials, citing incomplete safety warning
Endpoints
Karyopharm
Selinexor
clinical trials
FDA
Flag link:
Karyopharm sets a course for the FDA with positive PhIIb multiple myeloma data
Karyopharm sets a course for the FDA with positive PhIIb multiple myeloma data
Endpoints
Karyopharm
FDA
clinical trials
Multiple Myeloma
Selinexor
Flag link:
3 Clinical-Stage Biotech Stocks With News About To Break
3 Clinical-Stage Biotech Stocks With News About To Break
Motley Fool
Novavax
RSV F vaccine
Agile Therapeutics
birth control patch
Twirla
Karyopharm
Selinexor
Multiple Myeloma
Flag link:
10 Worst NASDAQ Biotech Stocks in the Third Quarter
10 Worst NASDAQ Biotech Stocks in the Third Quarter
TheStreet.com
Orexigen
Immunomedics
Celldex Therapeutics
Arena Pharmaceuticals
Theravance
Karyopharm
Raptor Pharmaceutical
Verastem
Tetraphase
Xoma
Flag link:
Karyopharm Therapeutics IPO Looks Promising
Karyopharm Therapeutics IPO Looks Promising
Seeking Alpha
Karyopharm
IPOs
Pfizer
Aveo Oncology
ONYX Pharmaceuticals
Flag link:
GlycoMimetics, Karyopharm ride the wave of new biotech IPOs
GlycoMimetics, Karyopharm ride the wave of new biotech IPOs
Fierce Biotech
IPOs
GlycoMimetics
Karyopharm
Selinexor
cancer
GMI-1070
sickle cell disease
Flag link: